MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX)

Today's Latest Price: $12.30 USD

0.22 (1.82%)

Updated Sep 25 4:00pm

Add MGTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MGTX Daily Price Range
MGTX 52-Week Price Range

MGTX Stock Price Chart Technical Analysis Charts

MGTX Price/Volume Stats

Current price $12.30 52-week high $22.32
Prev. close $12.08 52-week low $8.82
Day low $12.01 Volume 46,165
Day high $12.56 Avg. volume 115,765
50-day MA $13.39 Dividend yield N/A
200-day MA $15.11 Market Cap 459.56M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio

MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.

MGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream

Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting

\- Nine-Month Follow-Up Data to be Presented -LONDON and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month results from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP), will be presented in an oral session at the EURETINA 2020 Virtual Meeting taking place October 2-4, 2020.Details of the presentation are listed below. Data is embargoed until the date and time of presentation.Title: Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results Presenter: Michel Michaelides, BSc MB BS MD(Res) FRCOphth FACS...

Yahoo | September 22, 2020

MeiraGTx EPS misses by $0.14

MeiraGTx (MGTX): Q2 GAAP EPS of -$0.69 misses by $0.14.Revenue of $2.47M (+24.7% Y/Y)Cash and cash equivalents of $194.8M.Press Release...

Seeking Alpha | August 6, 2020

MeiraGTx Reports Second Quarter 2020 Financial Results

\- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented \- AAV-RPGR to advance into Phase 3 Lumeos clinical trial \- Expands manufacturing capabilities with new facilities in IrelandLONDON and NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent clinical development and business progress, including the Company’s new cGMP viral vector manufacturing and plasmid production facilities in Shannon, Ireland.“The first half of 2020 has been marked by notable achievements for MeiraGTx, including the recent presentation of positiv...

Yahoo | August 6, 2020

MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO).A clinical immunologist by training, Dr. Zeldin brings more than 20 years of clinical, regulatory and industry experience to MeiraGTx, ranging from early-stage clinical development through Biologics License Application (BLA) filing and commercialization.“Dr. Zeldin is an experienced drug developer with a distinguished track record in the design and implementation of successful clinical development strategies,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “As we advance the MeiraGTx pipeline into late-stage deve...

Yahoo | August 5, 2020

MeiraGTx Sees Hammer Chart Pattern: Time to Buy?

MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.

Yahoo | July 27, 2020

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo -4.87%
3-mo 0.74%
6-mo -8.48%
1-year -22.35%
3-year N/A
5-year N/A
YTD -38.56%
2019 107.68%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5671 seconds.